Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer

Kerri M. Winters-Stone, Nathan Dieckmann, Gianni F. Maddalozzo, Jill A. Bennett, Christopher W. Ryan, Tomasz M. Beer

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Purpose/Objectives: To determine whether exercise could reduce biomarkers of cancer progression in prostate cancer survivors (PCSs) on androgen-deprivation therapy (ADT). Design: Randomized, controlled trial. Setting: Oregon Health and Science University School of Nursing. Sample: 51 PCSs randomized to one year of resistance and impact training or a stretching control group. Methods: The authors investigated changes in body composition and cancer-related biomarkers, and the influence of age and fat loss on changes in biomarkers. Main Research Variables: Body composition (total fat, trunk fat, and lean mass), insulin, insulin-like growth factor-1, and sex hormone-binding globulin. Findings: In the 36 PCSs with baseline and 12-month data, total fat (p = 0.02) and trunk fat (p = 0.06) mass decreased in the training group compared to gains in controls. Loss of total and trunk fat each mediated the relationship between groups and one-year change in insulin (p < 0.05). Age moderated the insulin response to exercise where insulin reductions were smaller with increasing age (p = 0.03). Conclusions: Resistance and impact exercise may reduce body fat among PCSs undergoing ADT, in turn exerting an insulin-lowering effect. Implications for Nursing: Nurses should counsel PCSs to exercise to reduce the risk of obesity and associated conditions, including cancer progression.

Original languageEnglish (US)
Pages (from-to)348-356
Number of pages9
JournalOncology nursing forum
Issue number4
StatePublished - Jul 1 2015


  • Body composition
  • Obesity
  • Physical activity
  • Weight training

ASJC Scopus subject areas

  • Oncology(nursing)


Dive into the research topics of 'Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this